안구건조증 시장 규모는 2024년 62억 8,000만 달러로 평가되었고, 2026-2032년 연평균 4.50% 성장하여 2032년에는 86억 5,000만 달러에 달할 것으로 예측됩니다.
안구건조증은 각막염이라고도 불리는데, 눈물이 눈에 충분한 윤활유를 공급하지 못할 때 발생하는 증상입니다.
안구건조증(DES)은 원형각결막염(keratoconjunctivitis sicca)이라고도 불리며, 눈에서 분비되는 눈물의 질과 양이 감소하여 여러 가지 불쾌한 증상을 유발하고 시력 저하를 초래하는 흔한 질환입니다.
이 질환은 눈의 표면을 윤활하게 보호하는 눈물막이 눈물 분비 부족이나 눈물의 질 저하로 인해 파괴되어 발병합니다. 이 질환에는 노화, 기저질환, 갱년기 등의 호르몬 변화, 약물, 건조한 공기나 바람 등의 환경적 요인, 장시간 스크린 사용, 콘택트렌즈 착용 등 여러 가지 요인이 관여합니다.
DES의 증상으로는 가려움증과 작열감, 눈의 이물감, 충혈, 눈부심, 눈부심, 역설적 반응으로 인한 눈의 충혈, 빛에 대한 과민반응 등이 있습니다.
안구건조증을 치료하지 않고 방치하면 각막 손상과 시력장애를 유발할 수 있기 때문에 조기 진단과 치료가 우수한 눈 건강을 유지하고 후유증을 남기지 않기 위해 중요합니다.
안구건조증에는 여러 가지 치료법이 있습니다. 눈물 분비를 보충하는 인공누액, 코르티코스테로이드, 사이클로스포린 등의 처방약이 있습니다.
또한 눈꺼풀의 피지선을 건강하게 유지하기 위한 위생용품도 있습니다. 눈물 배출관을 막고 눈물이 눈 표면에 오래 머물도록 하기 위해 눈물점 플러그를 사용하기도 합니다. 스크린 사용 시간 제한, 가습기 사용, 알레르기 유발 물질을 피하는 등 생활 습관을 개선하는 것도 도움이 됩니다. 콘택트렌즈는 건조한 상태에 적합합니다.
세계 안구건조증 시장을 형성하는 주요 시장 역학은 다음과 같습니다.
유병률 증가: 전 세계적으로 안구건조증 빈도가 증가하는 것은 인구 고령화, 디지털 기기의 장시간 사용, 환경적 요인, 전신 질환 등에 기인하고 있습니다. 안구건조증 유병률이 증가함에 따라 효과적인 치료 옵션에 대한 수요도 증가하여 시장 성장을 견인하고 있습니다.
인식 제고 및 진단: 환자 및 의료진의 인식이 높아짐에 따라 안구건조증 진단율이 증가하고 있습니다. 인식 제고 캠페인, 교육 이니셔티브, 검진 프로그램 등은 모두 조기 발견 및 조기 개입을 촉진하고 안구건조증 치료 시장의 성장에 기여하고 있습니다.
고령자 증가: 눈물의 성분과 분비량은 연령에 따라 차이가 있기 때문에 고령자는 특히 안구건조증에 걸리기 쉽습니다. 세계 인구의 급속한 고령화에 따라 안구건조증 유병률이 증가하면서 치료 및 관리 전략에 대한 수요가 증가하고 있습니다.
장시간 스크린 사용 및 디지털 기기 사용: 컴퓨터, 태블릿, 스마트폰 등 디지털 기기의 잦은 사용은 안구건조증 위험 증가와 관련이 있습니다. 장시간 화면 사용은 눈 깜박임 횟수를 줄이고 눈 표면을 자극하여 증발성 안구건조증을 유발하여 치료의 필요성을 높입니다.
치료법 기술 개발: 안과 기술과 약리학의 기술 발전으로 인해 보다 내약성이 높고 효과적인 새로운 안구건조증 치료법이 개발되고 있습니다. 혁신적인 제형, 약물 전달 시스템 및 의료기기는 안구건조증 증상 관리를 개선하고 시장 확대의 원동력이 되고 있습니다.
R&D 활동 증가: 제약회사, 바이오테크놀러지 기업, 학술기관의 연구개발(R&D)에 대한 막대한 투자가 안구건조증에 대한 새로운 치료 접근법 및 치료법 개발을 촉진하고 있습니다. 이러한 지속적인 연구 개발 노력은 시장 확대와 기술 혁신을 촉진하고 있습니다.
개인 맞춤형 의료로의 전환: 개인 맞춤형 의료로의 전환은 안구건조증 관리에도 영향을 미칩니다. 안구건조증은 예측할 수 없는 질환이며, 환자 개개인의 특성이 다르기 때문에 맞춤형 치료가 인기를 끌고 있습니다. 맞춤형 치료와 병용요법은 더 나은 결과를 가져오고 환자 만족도를 높여 시장 성장을 가속화하고 있습니다.
주요 과제
지식 부족: 안구건조증에 대한 인식 부족이 안구건조증 시장의 성장을 제한하고 있습니다. 많은 사람들이 안구건조증, 자극감, 불편감 등의 증상을 대수롭지 않게 여기거나 의학적 문제와 무관한 것으로 치부하여 진단과 치료가 제대로 이루어지지 않고 있습니다.
진단의 어려움: DES는 다른 안질환과 증상이 일치하기 때문에 진단이 어렵습니다. 문진, 안구 표면 염색, 눈물 분석 등 현재의 진단 기술로는 필요한 민감도와 특이도를 얻지 못하는 경우가 많아 진단이 늦어지거나 잘못된 진단이 내려지기도 합니다.
치료 접근 방식의 복잡성: 환자가 DES 치료 요법을 준수하는 것은 어려운 일이며, 특히 잦은 복용과 생활습관 조절이 필요한 약물 요법의 경우 더욱 그렇습니다. 비용, 인지된 효과, 불편함, 불편함 등이 모두 순응도에 영향을 미칠 수 있습니다.
특이성과 치료법 부족: 특히 보험이 적용되지 않거나 본인부담금이 터무니없이 높은 경우, DES 치료비가 큰 걸림돌이 되기도 합니다. 이러한 가격 부담은 경제적으로 여유가 없는 환자들에게 특수 장비나 병원 내 시술, 고가의 처방약 구매를 망설이게 할 수 있습니다.
규제적 장애물: 규제적 장애물은 새로운 DES 치료법을 도입하는 데 있어 가장 큰 걸림돌입니다. 규제 당국의 평가와 승인은 비용과 시간이 많이 소요됩니다. 새로운 치료법을 연구하는 기업들은 유효성과 안전성을 입증하기 위해 엄격한 법적 요건을 통과해야 하는데, 이는 큰 도전이 될 수 있습니다. 이러한 규제 요건은 새로운 치료법의 출시를 방해할 수 있습니다.
주요 동향
유병률 증가와 인식 개선: 전 세계적으로 고령화가 진행되면서 안구건조증은 큰 위험요소가 되고 있습니다. 또한, 디지털화된 라이프스타일로 인해 스크린 사용 시간이 증가하면서 안구건조증 발병이 가속화되고 있습니다. 안구건조증의 증상과 치료 옵션에 대한 대중의 인식이 높아짐에 따라 더 많은 사람들이 진단을 받고 시장 기회가 확대될 것입니다.
조기 진단과 예방 치료의 중요성: 안구건조증의 조기 발견과 조기 치료의 중요성이 강조되면서 예방 안과 의료가 중요시되고 있습니다. 보다 간편하고 이용하기 쉬운 진단 기술의 개발로 조기 진단이 가능해져 환자의 예후를 개선할 수 있습니다.
혁신적인 치료법: 제약회사들은 특히 안구건조증에 대한 허가된 신약을 지속적으로 개발하여 보다 안전하고 환자에게 적합한 치료법을 제공합니다. 약물 전달 기술의 발전으로 효능이 높고 윤활 효과가 오래 지속되는 새로운 안약이 개발되고 있습니다. 항염증제나 신경영양인자 등의 새로운 치료법은 안구건조증의 근본적인 원인을 치료하는 데 유망한 치료법입니다.
기술의 발전: 안구건조증 평가 및 치료를 위해 환자가 안과 의사에게 쉽게 접근할 수 있도록 원격 진료가 인기를 끌고 있습니다. 인공지능(AI)을 진단 도구에 사용함으로써 안구건조증 진단의 정확성과 효율성을 높일 수 있습니다.
개인 맞춤형 의료: 안구건조증 산업은 환자 개개인의 특성과 안구건조증 유형에 따라 치료 프로그램을 조정하는 맞춤형 의료 접근방식으로 전환하고 있습니다. 이러한 맞춤형 전략은 보다 효과적인 질병 관리로 이어질 수 있는 잠재력을 가지고 있습니다.
온라인 소매의 부상: 온라인 소매 플랫폼의 확산으로 시판되는 안구건조증 치료제에 쉽게 접근할 수 있게 되면서 기존 유통 채널에 영향을 미치고 있습니다. 이러한 움직임으로 환자들은 집에서 편리하게 중요한 치료제를 구매할 수 있게 되었습니다.
Dry Eye Syndrome Market size was valued at USD 6.28 Billion in 2024 and is projected to reach USD 8.65 Billion by 2032, growing at a CAGR of 4.50% from 2026 to 2032.
Dry eye syndrome, also known as keratoconjunctivitis sicca is a condition that occurs when your tears aren't able to provide adequate lubrication for your eyes.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca, is a common disorder that reduces the quality and number of tears produced by the eyes, causing a variety of unpleasant symptoms and perhaps impairing eyesight.
This disorder develops when the tear film, which lubricates and protects the eye's surface, is disrupted owing to insufficient tear production or poor tear quality. Several factors contribute to this disruption, including aging, underlying medical disorders, hormonal changes such as menopause, drugs, environmental factors like as dry air and wind, prolonged screen time, and contact lens wear.
DES symptoms include a scratchy or burning sensation, a sense of something foreign in the eye, redness, blurred vision, moist eyes as a paradoxical reaction, and light sensitivity.
If left untreated, dry eye can develop and cause corneal damage and vision issues, therefore early diagnosis and treatment are critical for preserving excellent eye health and avoiding consequences.
There are several therapy options available for dry eye conditions. These include artificial tears to supplement tear production, prescription drugs such as corticosteroids, cyclosporine,
These are also used to treat underlying inflammation or increase tear production, and eyelid hygiene items to keep the oil glands in the eyelids healthy. Punctal plugs can also be used to obstruct tear drainage ducts, allowing tears to stay on the eye's surface for an extended period of time. Lifestyle changes, such as limiting screen time, using a humidifier, and avoiding allergens, can all be beneficial. Contact lenses are suited for arid conditions.
The key market dynamics that are shaping the global dry eye syndrome market include:
Growing Prevalence: The increasing frequency of dry eye syndrome worldwide is being pushed by aging populations, prolonged use of digital gadgets, environmental factors, and systemic illnesses. As the prevalence of dry eye conditions rises, so does the demand for effective treatment options, resulting in market growth.
Increasing Awareness and Diagnostics: Increased awareness among patients and medical professionals has resulted in a greater diagnostic rate for dry eye syndrome. Awareness campaigns, educational initiatives, and screening programs all help to promote early detection and intervention, which contributes to the growth of the dry eye therapy market.
Growing Older Population: Because of age-related differences in tear composition and production, the elderly are especially susceptible to dry eye syndrome. As the global population ages fast, the prevalence of dry eye syndrome rises, creating an increased demand for therapies and care strategies.
Extended Screen Time and Digital Device Usage: The frequent use of digital gadgets such as computers, tablets, and smartphones has been linked to an increased risk of dry eye syndrome. Extended screen time reduces blink rates, irritating the eye's surface and resulting in evaporative dry eye, increasing the necessity for therapies.
Technological Developments in Treatment Options: Technological advances in ophthalmic technology and pharmacology have resulted in the creation of novel dry eye treatments that are more tolerable and effective. Innovative medicine formulations, drug delivery systems, and medical devices are improving the management of dry eye symptoms, which is driving market expansion.
Increasing Research and Development Activities: Large investments in research and development (R&D) by pharmaceutical companies, biotechnology corporations, and academic institutions are propelling the development of new therapeutic approaches and treatments for dry eye. This continuing research and development effort is driving market expansion and innovation.
Transition to Personalized Medicine: The transition to customized medicine has an impact on the management of dry eye syndrome. Given the unpredictability of the ailment and the individual characteristics of each patient, customized medicine treatments are gaining popularity. Customized treatments and combination medicines produce better results and increase patient satisfaction, accelerating market growth.
Key Challenges
Lack of Knowledge: Lack of awareness of dry eye syndrome is limiting the growth of the dry eye syndrome market. Many people disregard symptoms such as dryness, irritation, and discomfort as insignificant or unrelated to a medical problem, resulting in underdiagnosis and treatment.
Difficult in Diagnosing: DES is difficult to diagnose since its symptoms coincide with those of other eye disorders. Current diagnostic techniques, like as questionnaires, ocular surface staining, and tear film analysis, frequently lack the required sensitivity and specificity, resulting in a delayed or incorrect diagnosis.
Complexity of Treatment Approaches: Patient commitment to DES treatment regimens can be difficult, particularly for medications that require frequent doses or lifestyle adjustments. Cost, perceived efficacy, inconvenience, and discomfort can all have an impact on adherence levels.
Lack of Specificity and Therapies: For some people, the cost of treating DES is a substantial obstacle, especially if insurance does not cover the therapies or the out-of-pocket payments are prohibitively expensive. This price burden may discourage patients with limited means from purchasing specialized devices, in-office procedures, or expensive prescription drugs.
Regulatory Obstacles: Regulatory hurdles provide challenges to the adoption of new DES treatments. The process of regulatory evaluation and approval is both expensive and time-consuming. Companies researching novel therapeutics must traverse tight legal requirements to establish efficacy and safety, which can be a significant challenge. These regulatory requirements can impede the availability of novel treatments on the market.
Key Trends:
Rising Prevalence and Increasing Awareness: The global aging population poses a substantial risk for dry eye syndrome. Furthermore, our digital lifestyles lead to increased screen time, which adds to the development of dry eyes. As the public becomes more aware of dry eye symptoms and treatment choices, more people are diagnosed, enhancing the market opportunity.
Focus on Early Diagnosis and Preventive Care: There is a rising emphasis on preventive eye care, emphasizing the significance of early detection and treatment of dry eye to avoid problems. The development of simpler and more accessible diagnostic technologies allows for earlier diagnoses, which can improve patient outcomes.
Innovative Treatment Options: Pharmaceutical companies are continually developing new drugs particularly licensed for dry eyes, providing safer and more tailored treatment approaches. Advances in medication delivery technologies are resulting in novel eye drops with higher potency and longer-lasting lubrication. Emerging therapeutics, such as anti-inflammatory medications and neurotrophic factors, show promise in treating the underlying causes of dry eye.
Technological Advancements: Telehealth consultations are gaining popularity, giving patients easier access to ophthalmologists for dry eye evaluation and treatment. The use of artificial intelligence (AI) in diagnostic tools can increase the accuracy and efficiency of dry eye detection.
Personalized Medicine: The industry is shifting toward customized medicine approaches, which adjust treatment programs based on individual patient characteristics and the type of dry eye they have. This tailored strategy has the potential to result in more effective disease management.
Rise in Online Retail: The increasing popularity of online retail platforms allows for easy access to over-the-counter dry eye products, which influences traditional distribution channels. This move enables patients to conveniently purchase critical treatments from the convenience of their own homes.
Here is a more detailed regional analysis of the global dry eye syndrome market:
North America
North America is substantially dominating the dry eye syndrome market and is anticipated to continue its dominance throughout the forecast period owing to the aging population, as older people are more prone to dry eyes.
Furthermore, the increasing use of digital devices lengthens screen time, which might exacerbate symptoms. Environmental factors such as dry air from air conditioning and heating systems contribute significantly to the region's high incidence of dry eye.
North America's healthcare infrastructure is highly developed, with a significant emphasis on implementing innovative technology and treatments. This innovative system enables the use of cutting-edge diagnostic tools and treatment choices for dry eye, ensuring that patients receive the best care possible.
Patients in North America typically have more disposable expenditures, allowing them to access a variety of dry eye remedies. This includes complex and possibly costly solutions including prescription drugs, specialty contact lenses, and novel therapeutic gadgets.
The capacity to afford such treatments helps to better control dry eye symptoms and enhance patient outcomes. Significant public awareness programs in North America have helped the general public understand dry eye conditions better.
These efforts promote early diagnosis and urge people to seek treatment sooner. As a result, there is an increasing need for dry eye treatment solutions, which is driving market growth.
North America is home to numerous large pharmaceutical businesses that play an important role in the dry eye market. Companies like Johnson & Johnson, with products like Acuvue Oasis with HydraMax, and Allergan, recognized for Restasis, are pioneering the development and distribution of dry eye therapies.
Their presence in the region contributes to continued research and innovation in the field. In North America, there is a major emphasis on researching and developing innovative dry eye treatments and technologies.
Pharmaceutical businesses and research organizations are actively attempting to provide more effective therapies, such as novel medication formulations and enhanced delivery systems.
This commitment to innovation guarantees that patients have access to the most recent and effective treatments. While certain dry eye treatments are covered by insurance in North America, there are still obstacles, especially with newer and more specialized drugs. These treatments may have substantial out-of-pocket costs, limiting patient access.
Asia Pacific
Asia Pacific is expected to be the fastest-growing region in the dry eye syndrome market during the forecast period owing to the substantial increase in the aging population. This demographic shift increases the likelihood of dry eye conditions, enlarging the patient pool and driving demand for effective therapies.
Patients in many Asian countries can now afford a wider selection of dry eye therapies thanks to rising disposable incomes. This economic expansion allows for increased healthcare spending, including advanced and potentially more expensive treatment choices for dry eye condition.
Across the Asia Pacific, public awareness campaigns and educational initiatives are increasing knowledge of dry eye symptoms and potential treatment choices. These efforts are critical in encouraging early diagnosis and treatment, which will boost the market.
The dry and dusty conditions found in certain parts of Asia Pacific contribute to the development of dry eye syndrome, driving up market demand. Pollution and seasonal changes are also key factors in aggravating symptoms.
With increased knowledge of eye health issues, there is a greater emphasis on preventive care and early intervention for illnesses such as dry eye syndrome. This proactive approach attempts to reduce the prevalence and impact of dry eye, hence improving general eye health in the population.
The growing use of new technology, such as telemedicine consultations, is increasing access to dry eye experts, especially in rural places. These technology advancements improve the quality and reach of eye care services, hence helping a larger number of patients.
The Global Dry Eye Syndrome Market is segmented based on Etiology and Severity, Demographics, Treatment Modalities, And Geography.
Based on the Etiology and Severity, the market is bifurcated into Evaporative Dry Eye, Aqueous Deficient Dry Eye, and Mixed/Multifactorial Dry Eye. The Evaporative Dry Eye segment is showing significant growth in the dry eye syndrome market owing to the rising prevalence of dry eye disease can be ascribed to variables such as increased screen time, decreased blinking rate, and age-related tear production. The widespread availability of medications such as EvoTears, which target the evaporative kind of dry eye, makes effective therapies more accessible.
Based on the Demographics, the market is bifurcated into Age, Gender, Work, and Lifestyle. The age segment is showing significant dominance in the dry eye syndrome market owing to the substantial association between rising age and decreased tear output. This represents a considerable business opportunity, particularly given the expanding older population. Products such as easy-to-use eye drops and preservative-free formulations are specifically intended to meet the demands of older adults, fueling growth in this market.
Based on the Treatment Modalities, the market is bifurcated into Artificial tears, Anti-inflammatory Agents, Lid Hygiene, and Warm Compresses. The artificial tears segment is showing significant dominance in the dry eye syndrome market as artificial tears are extensively used and provide symptomatic relief for the majority of dry eye conditions by lubricating the ocular surface. As a first-line therapy, they are preferred due to their ease of administration, non-invasive nature, and the availability of several formulations over the counter. Furthermore, the market offers a wide range of artificial tear formulations with varying viscosities and chemicals to fulfill individual requirements.
Based on Geography, the Global Dry Eye Syndrome Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is substantially dominating the dry eye syndrome market and is anticipated to continue its dominance throughout the forecast period owing to the aging population, as older people are more prone to dry eyes. Furthermore, the increased use of digital devices lengthens screen time, which might exacerbate symptoms. Environmental factors such as dry air from air conditioning and heating systems contribute significantly to the region's high incidence of dry eye.
The "Global Dry Eye Syndrome Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Allergan plc (AbbVie, Inc.), Novartis AG, Johnson & Johnson Vision Care, Inc., Bausch Health Companies, Inc., Santen Pharmaceutical Co., Ltd., Alcon Inc. (Novartis AG), Otsuka Pharmaceutical Co., Ltd., Shire plc (Takeda Pharmaceutical Company Limited), Sun Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.